1. Home
  2. GDS vs NUVL Comparison

GDS vs NUVL Comparison

Compare GDS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GDS Holdings Limited ADS

GDS

GDS Holdings Limited ADS

HOLD

Current Price

$47.36

Market Cap

8.2B

Sector

Technology

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$100.70

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDS
NUVL
Founded
2001
2017
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
7.1B
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
GDS
NUVL
Price
$47.36
$100.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
15
Target Price
$46.20
$135.00
AVG Volume (30 Days)
2.5M
570.1K
Earning Date
03-18-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.59
N/A
Revenue
$1,573,383,809.00
N/A
Revenue This Year
$13.03
N/A
Revenue Next Year
$12.55
N/A
P/E Ratio
$55.42
N/A
Revenue Growth
11.86
N/A
52 Week Low
$16.93
$55.54
52 Week High
$52.50
$113.02

Technical Indicators

Market Signals
Indicator
GDS
NUVL
Relative Strength Index (RSI) 68.46 45.28
Support Level $38.21 $105.05
Resistance Level $48.18 $113.02
Average True Range (ATR) 2.31 5.03
MACD 0.52 -0.10
Stochastic Oscillator 90.72 24.60

Price Performance

Historical Comparison
GDS
NUVL

About GDS GDS Holdings Limited ADS

GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia via the now 38% owned DayOne. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: